Pharming Group Receives Subsidies For Research In Osteoporosis
Leiden, The Netherlands, January 31, 2007. Biotech company Pharming Group NV ("Pharming" or "the Company") (Euronext: PHARM) announced today that its wholly owned subsidiary DNage has been granted two SenterNovem subsidies totalling just over EUR 1 million, over a period of three years, to develop products in the field of osteoporosis.